8-K: Cingulate Inc. Completes Final FDA Study for ADHD Drug CTx-1301, Targets Mid-2025 NDA Submission

Cingulate Inc. has completed its final FDA-required food effect study for CTx-1301, an ADHD treatment, with no serious adverse events reported and a New Drug Application submission targeted for mid-2025.

Summary

• Cingulate Inc. has completed the final FDA-required food effect study for its lead drug candidate, CTx-1301, which is intended to treat Attention Deficit Hyperactivity Disorder (ADHD).
• The study involved a single 50mg dose of CTx-1301 given to 26 healthy adult subjects to assess the impact of food on the drug's absorption.
• No serious adverse events were reported during the study.
• The company expects to release data on the bioavailability of CTx-1301 with and without food in the second quarter of 2025.
• Cingulate is targeting a New Drug Application (NDA) submission to the FDA for CTx-1301 in mid-2025.
• CTx-1301 is designed to be a once-daily stimulant medication for ADHD, utilizing a proprietary Precision Timed Release (PTR) platform to deliver three doses of medication throughout the day.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful completion of a key study and the clear timeline for the NDA submission. The absence of serious adverse events further supports a positive outlook.

Positives

• The completion of the food effect study is a significant milestone for CTx-1301's development.
• No serious adverse events were reported during the study, indicating a positive safety profile.
• The company is on track to submit an NDA to the FDA in mid-2025.
• CTx-1301 is designed to address the need for a true once-daily stimulant medication for ADHD.
• The PTR platform technology aims to improve drug delivery and patient outcomes.

Risks

• The company's success is dependent on the FDA's approval of CTx-1301.
• There is a risk that the bioavailability data readout in Q2 2025 may not be favorable.
• The company faces competition from other pharmaceutical companies developing ADHD treatments.
• The company's forward-looking statements are subject to various risks and uncertainties.

Future Outlook

Cingulate is focused on submitting a New Drug Application (NDA) for CTx-1301 to the FDA in mid-2025 and is exploring additional therapeutic areas for its PTR technology.

Management Comments

• Cingulate Chairman and CEO Shane J. Schaffer stated that the completion of the study marks another important milestone and is one of the final activities required for NDA submission to the FDA.
• Shane J. Schaffer also mentioned that they are developing CTx-1301 to be the first true, once-daily stimulant medication that treats ADHD over an entire active day.

Industry Context

The announcement is significant in the context of the ADHD treatment market, where there is a need for more effective and convenient once-daily medications. Cingulate's PTR technology aims to address this need by providing a more controlled and sustained release of medication.

Comparison to Industry Standards

• The current standard of care for ADHD often involves multiple daily doses of stimulant medications, which can be inconvenient for patients.
• Cingulate's CTx-1301 aims to differentiate itself by providing a true once-daily option, which could improve patient adherence and outcomes.
• Competitors in the ADHD market include companies like Shire (now Takeda), Novartis, and Teva, which offer various extended-release stimulant medications.
• Cingulate's PTR technology, if successful, could provide a competitive advantage by offering a more precise and controlled drug release profile compared to existing extended-release formulations.

Stakeholder Impact

• Shareholders may view the news positively as it represents progress in the development of CTx-1301.
• Patients with ADHD may benefit from a new once-daily treatment option.
• The company's employees are likely to be motivated by the progress of the drug development program.

Next Steps

• The company will analyze the data from the food effect study.
• Cingulate will release the bioavailability data in Q2 2025.
• The company will prepare and submit the New Drug Application (NDA) to the FDA in mid-2025.

Key Dates

Keywords

CTx-1301, ADHD, FDA, New Drug Application, Precision Timed Release, Dexmethylphenidate, Bioavailability, Food Effect Study, Pharmaceutical, Stimulant